NX-5948

DelveInsight's latest report reveals a robust pipeline with 20+ companies developing 22+ therapies for mantle cell lymphoma, highlighting significant advancement in treatment options for this rare blood cancer.

Nurix Therapeutics has appointed John Northcott, who led the commercialization of BTK inhibitor ibrutinib, as Chief Commercial Officer. The appointment comes as Nurix prepares to launch a pivotal clinical program for NX-5948, their BTK degrader that has shown a 75.5% objective response rate in heavily pretreated B-cell malignancy patients.

Nurix Therapeutics' NX-5948 demonstrates a 75.5% objective response rate in relapsed/refractory CLL/SLL patients in Phase 1 study.

Nurix Therapeutics' lead candidate, NX-5948, demonstrates significant potential in treating chronic lymphocytic leukemia and autoimmune diseases, with plans for registrational trials in 2025. Despite challenges, the company's strategic expansion and strong clinical data position it as a potential leader in the BTK degrader market.

The phase 3 AMPLIFY trial demonstrated that acalabrutinib plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival (PFS) in treatment-naive CLL patients.